- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05556135
Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nonalcoholic fatty liver disease (NAFLD) includes different types of liver damage, ranging from simple steatosis and nonalcoholic steatohepatitis (NASH) to liver cirrhosis and even hepatocellular carcinoma.(1) NAFLD is diagnosed by the presence of more than 5% fat accumulation in liver cells after excluding excessive alcohol intake in patients as well as other secondary causes of liver disease, such as drug-induced liver injury, viral and autoimmune hepatitis.(2) The diagnostic criteria for chronic kidney disease (CKD) are either the reduced estimated glomerular filtration rate (eGFR) (<60 mL/min/1.732) and/or abnormal albuminuria and/or overt proteinuria in patients for at least 3 months.(3) The association between NAFLD and CKD has recently attracted the attention of many experts. NAFLD and CKD share some common pathophysiological mechanisms as well as some metabolic risk factors for cardiovascular disease. Some studies have confirmed that the presence of NAFLD increases the risk of CKD and that the degree of liver fibrosis is related to CKD stage,(4) It is crucial to detect early renal impairment in patients with NAFLD to prevent CKD progression, minimize complications, and improve survival (1) Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.(4) Adiponectin is one of the key regulators involved in glucose and lipid metabolism. Further analyses have shown its anti-inflammatory and anti-apoptotic roles in human cells.
Data from large cross sectional studies showed a positive correlation between serum Adiponectin and mortality in chronic kidney disease.(5)
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Mustafa Abdelrafie, master
- Phone Number: 01010303737
- Email: mustafabadary@yahoo.com
Study Contact Backup
- Name: mohamed elyamany, MD
- Phone Number: 01002228914
- Email: elyamany50@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All patients who fulfil inclusion and exclusion criteria then directed to nephrology unit to do other full investigations ,will be included in this study .
1)Full history and clinical examination .2) Investigation :
All patients will be investigated for detection of renal impairment by :
1)microalbuminurea.
- 2)Urine analyses.
- 3)Kidney function tests.
- 4)calculate GFR.
- 5)Complete blood count .
And also to detect the degree of liver affection by:
- 1)liver function tests .
- 2)abdominal ultrasound to grade fatty liver & determine echogenicity of kidney .
3)Non-invasive blood test to detect degree of hepatic steatosis ( FIB-4 , APRI, fibrosis score ).
4)fibroscane .
- Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA *Investigations to control risk factors of Non-alcoholic fatty liver disease: -Calculate Body Mass Index (BMI). - Measuring the fasting blood sugar and HbA1C level in all subjects. -Lipid Profile.
Description
Inclusion Criteria:
- Patients with fatty liver aged from 18 to 60 yrs either diabetic or not .
- Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2.
- The Control group are completely healthy subjects without any systemic or liver and kidney affection
Exclusion Criteria:
- 1)Patients less than 18 yrs & more than 60 yrs 2)All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
group1
NAFLD patients
|
estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
|
group 2
non NAFLD patients
|
estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.
Time Frame: baseline
|
Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.
/
|
baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: mohamed hassan, MD, master
Publications and helpful links
General Publications
- Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol. 1983 Nov;97(5 Pt 1):1648-52. doi: 10.1083/jcb.97.5.1648.
- Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res. 2002 Sep;34(9):469-74. doi: 10.1055/s-2002-34785.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Serum Adiponectin in NAFLD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Impairment
-
Eisai Inc.CompletedHepatic Impairment; Renal ImpairmentUnited States
-
JW PharmaceuticalCompletedHealthy, Renal ImpairmentKorea, Republic of
-
Kowa Research Institute, Inc.CompletedSevere Renal ImpairmentUnited States
-
Centre for Probe Development and CommercializationSt. Joseph's Healthcare Hamilton; McMaster UniversityCompleted
-
Gilead SciencesTerminatedSevere Renal ImpairmentUnited States
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Affiliated Hospital of Zhengzhou UniversityCompletedChronic Renal ImpairmentChina
-
Novartis PharmaceuticalsCompletedMild and Moderate Renal ImpairmentRussian Federation, Germany, Serbia
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Severe Renal ImpairmentCzechia
-
Melbourne HealthWithdrawnRenal Impairment After Cardiac SurgeryAustralia
-
AstraZenecaCompletedRenal Impairment | Hepatic ImpairmentBulgaria
Clinical Trials on level of serun adiponectin
-
The Cooper Health SystemUnknown
-
Zeynep Kamil Maternity and Pediatric Research and...CompletedPostpartum DepressionTurkey
-
Ankara City Hospital BilkentCompleted
-
Assiut UniversityCompleted
-
Osijek University HospitalRecruitingSystemic Inflammatory Response Syndrome | Postoperative Complications | Surgery | Obesity, AbdominalCroatia
-
Duke UniversityCompletedOverweight, Obesity, Small for Gestational Age, PrematurityUnited States
-
Johns Hopkins Bloomberg School of Public HealthCompleted
-
University Hospital, ToulouseNot yet recruiting
-
Ruijin HospitalCellular Biomedicine Group Ltd.Completed
-
Shanghai Zhongshan HospitalRecruiting